Committee for Medicinal Products for Human Use CHMP Recommends Marketing Authorisation of the COVID-19 Vaccine Nuvaxovid for Booster Vaccinations

On 1 September 2022, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) recommended issuing a marketing authorisation for the protein-based vaccine Nuvaxovid as a booster dose for adults who received either the same or a different COVID-19 vaccine at the time of their first vaccination. The European Commission approved the marketing authorisation extension on 6 September 2022.